NICEVIVA
MONOGRAPH SPEC LATEST 2026

Forsythia suspensa

TRADITIONAL ASIAN · Evidence Monograph

Forsythia suspensa is an evidence-graded traditional asian monograph evaluated across 43 peer-reviewed PubMed studies (1 meta-analyses, 2 systematic reviews, and 0 randomized controlled trials, encompassing n = 2,313 cumulative participants). Current clinical evidence is rated GRADE Moderate (3.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) Moderate (3.0 / 4.0)
Indexed PubMed Studies 43 Studies
Meta-Analyses · Reviews 1 Meta · 2 Systematic Reviews
Randomized Trials (RCT) 0 RCTs (0 Double-Blind)
Cumulative Participants n = 2,313
Reported Trial Dosages 1.7 g · 1.3 g · 200 mg
Trial Duration Range 12 days · 15 days · 7 days
Reading Time ~22 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 43 indexed PubMed studies, GRADE Moderate).
  2. 02 Adults matching clinical trial dosing protocols (1.7 g · 1.3 g · 200 mg) over a structured 12 days evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
With Breakfast or Lunch
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary traditional asian clinical efficacy (43 PubMed studies)
Quantitative biomarker & outcome analysis (10 studies with effect-size/sample data)
Randomized controlled trial verification (0 RCTs · 0 double-blind)
Systematic review & meta-analysis synthesis (1 meta-analyses · 2 reviews)
01

What Is Forsythia suspensa & Why Does Form Matter?

Forsythia suspensa is classified under TRADITIONAL ASIAN and has been investigated across 43 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (1.7 g, 1.3 g, 200 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Forsythia suspensa frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (0 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Forsythia suspensa acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Forsythia suspensa an overall evidence rating of GRADE Moderate (3.0 / 4.0) based on 43 PubMed studies: 1 meta-analyses, 2 systematic reviews, and 0 randomized controlled trials (0 double-blind, n = 2,313 total participants).

Representative peer-reviewed findings include: • PMID:41152613 (2026) — "Integrative network pharmacology and experimental validation of multi-target synergy against multidrug-resistant klebsiella pneumoniae via PI3K/AKT-MAPK pathway disruption." (In Conclusion, this study unveils a triple-action mechanism of luteolin-wogonin-kaempferol against MDR-KP, simultaneously disrupting resistance pathways, biofilms, and hyperinflammation.) • PMID:24864291 (2014) — "Forsythia suspensa extract attenuates corticosterone-induced growth inhibition, oxidative injury, and immune depression in broilers." (In conclusion, dietary FSE supplementation enhanced nutrient digestibility and performance of broiler possibly by reducing oxidative stress and immune depression challenged by CS.) • PMID:33234322 (2021) — "Experimental study of Forsythoside A on prevention and treatment of avian infectious bronchitis." (A number of results showed that Forsythoside A had both preventive and therapeutic effects in IBV-M41-infected chickens, among which the high-dose (80 mg/kg/d) prevention group,the high- (80 mg/kg/d) and medium (40 mg/kg/d) -dose treatment group had significant effects.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 1.7 g · 1.3 g · 200 mg · 100 mg over 12 days · 15 days · 7 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Forsythia suspensa, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (1.7 g · 1.3 g · 200 mg) and re-evaluate efficacy after 12 days.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (43 Studies) · 10 Quantitative Analyses

01
CLINICAL STUDY Naunyn-Schmiedeberg's archives of pharmacology (2026) PMID: 41152613 ↗
Integrative network pharmacology and experimental validation of multi-target synergy against multidrug-resistant klebsiella pneumoniae via PI3K/AKT-MAPK pathway disruption.
Clinical Trial Synthesis 2026 Clinical Study published in Naunyn-Schmiedeberg's archives of pharmacology; statistical significance reported at p = 0.001. Key conclusion: In Conclusion, this study unveils a triple-action mechanism of luteolin-wogonin-kaempferol against MDR-KP, simultaneously disrupting resistance pathways, biofilms, and hyperinflammation.
View Original PubMed Abstract ↓

Multidrug-resistant Klebsiella pneumoniae (MDR-KP) infections present a global health crisis, with escalating resistance to last-line antibiotics. Traditional Chinese medicines (TCMs) demonstrate multi-component synergy against resistant pathogens. This study deciphered the antibacterial mechanisms of bioactive TCM components targeting MDR-KP through integrative pharmacology and experimental validation. Four core TCMs (Scutellaria baicalensis, Forsythia suspensa, Lonicera japonica, Aloe vera) were screened via Chinese Pharmacopoeia and TCMSP database. Network pharmacology identified core components and enriched pathways. Clinically isolated MDR-KP strains (resistant to meropenem, polymyxin E, and tigecycline) were characterized. Synergistic effects were evaluated using checkerboard assays, biofilm quantification, and membrane permeability assays. Molecular docking and RT-qPCR analyzed target interactions, while ELISA and CCK-8 assessed anti-inflammatory activity and cytotoxicity. Consequently, luteolin, wogonin, and kaempferol were identified as key components targeting PI3K/AKT and MAPK pathways. Their triple combination (2/4/8 μg/mL) exhibited potent synergy (FIC = 0.38), reducing biofilm biomass by 68% (p < 0.001) and extracellular polysaccharide thickness from 15.1 μm to 3.1 μm (p < 0.001). Flow cytometry confirmed a 144.8% increase in membrane permeability. Molecular docking revealed high-affinity binding to PI3K (- 6.78 kcal/mol), AKT1 (- 6.60 kcal/mol), and MAPK1 (- 7.24 kcal/mol), with RT-qPCR showing significant downregulation of these genes (p < 0.001). The combination suppressed LPS-induced TNF-α and IL-6 release by 72% and 65%, respectively, while maintaining 95.5% cell viability at therapeutic concentrations. In Conclusion, this study unveils a triple-action mechanism of luteolin-wogonin-kaempferol against MDR-KP, simultaneously disrupting resistance pathways, biofilms, and hyperinflammation. The regimen offers a safe, multi-target therapeutic strategy for combating drug-resistant infections. © 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

02
CLINICAL STUDY Poultry science (2014) PMID: 24864291 ↗
Forsythia suspensa extract attenuates corticosterone-induced growth inhibition, oxidative injury, and immune depression in broilers.
Clinical Trial Synthesis 2014 Clinical Study published in Poultry science; statistical significance reported at p = 0.01. Key conclusion: In conclusion, dietary FSE supplementation enhanced nutrient digestibility and performance of broiler possibly by reducing oxidative stress and immune depression challenged by CS.
View Original PubMed Abstract ↓

Forsythia suspensa extract (FSE) has been demonstrated to attenuate physiological stress induced by high temperature or high stocking density. This experiment was conducted with 144 male Arbor Acre broilers (1-d-old, weighing 42.7 ± 1.7 g) to determine the effects of FSE on performance, nutrient digestibility, antioxidant activities, serum metabolites, and immune parameters for birds treated with corticosterone (CS). The birds were randomly allotted to 1 of 4 treatments in a 2 × 2 factorial arrangement that included FSE supplementation (0 or 100 mg/kg) and CS administration (0 or 20 mg/kg of diet for 7 consecutive days starting on d 14). The feeding program consisted of a starter diet from d 1 to 21 and a finisher diet from d 22 to 42. Corticosterone administration decreased (P < 0.01) ADG and impaired (P < 0.01) feed conversion ratio in both phases and overall, which were alleviated (P < 0.01) by dietary FSE supplementation in the finisher phase and overall. At d 21, CS administration caused decreases (P < 0.05) in the apparent digestibility of energy, relative weight of bursa and thymus, total antioxidant capacity, superoxide dismutase (SOD) activity, and antibody titers to Newcastle disease virus (NDV); however, serum malondialdehyde and uric acid were increased. All of these changes were attenuated (P < 0.05) by dietary FSE supplementation. At d 42, FSE supplementation improved (P < 0.05) the apparent digestibility of DM and CP, relative weights of bursa, SOD activity, and antibody titers to NDV, which were impaired by CS administration. Interactions (P < 0.05) were noted between CS and FSE for ADG and feed conversion ratio in the finisher phase and overall, as well as total antioxidant capacity, SOD activity, uric acid, and antibody titers to NDV at d 21, as well as relative weights of thymus at d 42. In conclusion, dietary FSE supplementation enhanced nutrient digestibility and performance of broiler possibly by reducing oxidative stress and immune depression challenged by CS. © 2014 Poultry Science Association Inc.

03
CLINICAL STUDY Research in veterinary science (2021) PMID: 33234322 ↗
Experimental study of Forsythoside A on prevention and treatment of avian infectious bronchitis.
Clinical Trial Synthesis 2021 Clinical Study published in Research in veterinary science; statistical significance reported at p = 0.05. Key conclusion: A number of results showed that Forsythoside A had both preventive and therapeutic effects in IBV-M41-infected chickens, among which the high-dose (80 mg/kg/d) prevention group,the high- (80 mg/kg/d) and medium (40 mg/kg/d) -dose treatment group had significant effects.
View Original PubMed Abstract ↓

Forsythoside A is the main active ingredient in the Chinese medicine Forsythia suspensa, which has antiviral, anti-inflammatory, antioxidation, and immunoregulatory effects. It is reported that Forsythoside A can significantly inhibit the replication of the avian infectious bronchitis virus(IBV) in cells, but there is no report in chickens. The present study aimed to investigate the effect of Forsythoside A on IBV-M41, experiments were designed using 120 chickens at 12 days of age. The chickens were randomly divided into eight groups: Forsythoside A high-, medium-, and low-dose prevention groups, Forsythoside A high-, medium-, and low-dose treatment groups, model control group and normal control group. All chickens, except the normal control group, were inoculated with 0.2 ml of IBV-M41 at 15 days of age.The antiviral effects were evaluated by clinical signs, weight, histopathology, T-,B-lymphocyte proliferation, T-lymphocyte subsets and cytokine levels.The results showed that the infection rate in each Forsythoside A prevention group was significantly lower than that in the treatment group and model control group (P < 0.05). The recovery rate in each Forsythoside A treatment group was significantly higher than that in the model control group (P < 0.05), and the recovery rate in high- and medium-dose treatment group was the highest, at up to 86.67%. Lymphocytic transformation ability significantly improved in the prevention and treatment groups. Forsythoside A significantly improved the CD3+, CD4+, and CD8+ T-lymphocyte of infected chickens. The cytokine level was able to maintain high concentrations of IL-2 and IFN-α for a long time and maintain a dynamic IL-4-concentration balance. A number of results showed that Forsythoside A had both preventive and therapeutic effects in IBV-M41-infected chickens, among which the high-dose (80 mg/kg/d) prevention group,the high- (80 mg/kg/d) and medium (40 mg/kg/d) -dose treatment group had significant effects.

04
CLINICAL STUDY Poultry science (2008) PMID: 18577607 ↗
Effects of Forsythia suspensa extract on growth performance, nutrient digestibility, and antioxidant activities in broiler chickens under high ambient temperature.
Clinical Trial Synthesis 2008 Clinical Study published in Poultry science; statistical significance reported at p = 0.05. Key conclusion: Dietary supplementation with Forsythia suspensa extract can enhance nutrient digestibility and growth performance possibly by reducing oxidative stress of broiler chickens under high ambient temperatures.
View Original PubMed Abstract ↓

A 42-d trial was conducted with 252 broiler chickens (d 1 of age, 38.8 +/- 1.3 g of BW) to determine the effects of Forsythia suspensa extract on growth performance, nutrient digestibility, and antioxidant activities under high ambient temperature (32 +/- 1 degrees C). The feeding program consisted of a starter diet from d 1 to 21 of age and a finisher diet from d 22 to 42 of age. Dietary treatments included a negative control group (NC) fed a cornsoybean meal based diet without vitamin C or Forsythia suspensa extract, a positive control group fed a diet with 200 mg of vitamin C/kg, and a test group (FS) fed with 100 mg of Forsythia suspensa extract/kg. There were 14 cages per treatment and 6 birds per cage during the study. Birds had free access to diets and water during the entire period. Body weight and feed intake were measured at d 21 and 42. Blood and tissue samples were collected at d 21 and 42 for assay of antioxidant indices. Growth performance did not differ among treatment groups during the starter period. In the finisher phase, birds in FS had greater (P < 0.05) average daily gain, feed conversion, and apparent digestibility of energy, CP, calcium, and phosphorus than birds in NC. Furthermore, birds in FS had greater (P < 0.05) total antioxidant capacity and superoxide dismutase activity and lower (P < 0.05) malondialdehyde activity in the serum than birds in NC. The FS birds had greater (P < 0.05) muscle superoxide dismutase activity and lower (P < 0.05) malondialdehyde than NC birds. During the entire period, hepatic superoxide dismutase activity of FS birds was greater (P < 0.05) than that of NC birds. Dietary supplementation with Forsythia suspensa extract can enhance nutrient digestibility and growth performance possibly by reducing oxidative stress of broiler chickens under high ambient temperatures.

05
CLINICAL STUDY Arhiv za higijenu rada i toksikologiju (2026) PMID: 41944402 ↗
Forsythoside A attenuates metabolic dysfunction in type 2 diabetic mice by inhibiting the MAPK and activating the Nrf2 signalling pathways.
Clinical Trial Synthesis 2026 Clinical Study published in Arhiv za higijenu rada i toksikologiju. Key conclusion: In conclusion, forsythoside A demonstrated therapeutic effects akin to those of 150 mg/kg metformin and may be a promising candidate for clinical application.
View Original PubMed Abstract ↓

Forsythoside A, a natural phenylethanoid glycoside extracted from the weeping forsythia (Forsythia suspensa), exhibits a wide range of pharmacological activity, including antibacterial, hepatoprotective, antioxidant, neuroprotective, antiviral, and anti-inflammatory. The aim of this study was to determine its anti-hyperglycaemic and antioxidative effects in a diabetic mouse model (created by administering high-fat diet alongside successive low doses of streptozotocin) by measuring fasting blood glucose levels, body weight, food and water intake, oxidative stress, and histopathological changes. Diabetic mice received either forsythoside A (30 or 60 mg/kg bw) or metformin (150 mg/kg) as standard type 2 diabetes medication for comparison. After four weeks of administration, forsythoside A significantly increased body weight and reduced food and water intake at both doses, while the higher, 60 mg/kg dose also significantly reduced fasting blood glucose and had a similar effect on all these parameters as metformin. The higher, 60 mg/kg dose also had similar antioxidative effects as metformin in lowering malondialdehyde (MDA) and reactive oxygen species (ROS) and in elevating the antioxidant superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) levels. Moreover, at 60 mg/kg forsythoside A attenuated lipid accumulation in diabetic mice by elevating high-density lipoprotein cholesterol (HDL-C) and lowering total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), showing comparable effect to metformin. Similar improvements were observed by histopathological changes in the liver. Forsythoside A also lowered insulin levels in diabetic mice by up-regulating p-IRS-1 and inhibited the mitogen-activated protein kinase (MAPK) pathway by lowering the expressions of the p-p38 and p-JNK proteins. At the same time, it promoted the Nrf2 pathway by increasing Nrf2 and HO-1 expressions relative to untreated diabetic mice. In conclusion, forsythoside A demonstrated therapeutic effects akin to those of 150 mg/kg metformin and may be a promising candidate for clinical application. Publisher: Forsitozid A prirodni je feniletan

06
CLINICAL STUDY Journal of separation science (2026) PMID: 41578427 ↗
Screening Potential Anti-Respiratory Syncytial Virus Substances From Forsythia suspensa Using a High-Expressing Fusion Protein Cell Membrane Chromatography.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of separation science. Key conclusion: In conclusion, our findings provide a convenient, fast, and accurate method to screen potential anti-RSV ingredients in natural herbal medicines.
View Original PubMed Abstract ↓

Respiratory syncytial virus (RSV) imposes a substantial health burden, particularly among pediatric and elderly populations. The RSV fusion (F) protein, a critical mediator of viral entry and syncytium formation, represents a promising and rational target for antiviral drug development. Forsythia suspensa (Lianqiao in Chinese), a traditional Chinese medicinal herb, has been empirically employed for decades in the prevention of viral infections; however, its pharmacologically active constituents remain poorly characterized. The present investigation developed a high-expression F protein cell membrane chromatography system, and integrated with UHPLC-MS, to screen pharmacological substances from FS and verified the anti-viral potential against RSV in vivo. Our study pinpointed Forsythoside A, Forsythoside B, Phillygenin, and Phillyrin as potential anti-RSV compounds in FS. The research findings suggest that Forsythoside A, Forsythoside B, and Phillygenin exhibit considerable suppressive effects on cell fusion induced by RSV, concurrently effectively diminishing the expression level of the F protein gene. In contrast, the inhibitory impact of Phillyrin seems relatively less potent. In conclusion, our findings provide a convenient, fast, and accurate method to screen potential anti-RSV ingredients in natural herbal medicines. These results may facilitate the development of RSV treatment. © 2026 Wiley‐VCH GmbH.

07
CLINICAL STUDY Molecules (Basel, Switzerland) (2025) PMID: 40942054 ↗
Optimization of the Chitosan-Assisted Extraction for Phillyrin and Forsythoside A from Forsythia suspensa Leaves Using Response Surface Methodology.
Clinical Trial Synthesis 2025 Clinical Study published in Molecules (Basel, Switzerland). Key conclusion: The core mechanism involves the formation of complexes between chitosan and the target bioactive ingredients, which significantly boosts their extraction efficiency.
View Original PubMed Abstract ↓

In this study, a green and efficient extraction methodology was developed by leveraging the unique properties of chitosan-namely its non-toxicity, biocompatibility, and adhesive nature-to enhance the recovery of bioactive ingredients from Forsythia suspensa leaves. The core mechanism involves the formation of complexes between chitosan and the target bioactive ingredients, which significantly boosts their extraction efficiency. To substantiate this mechanism, comprehensive characterization was performed using Powder X-ray Diffraction (PXRD), Fourier Transform Infrared Spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), Scanning Electron Microscopy (SEM), and molecular docking analyses. The results provided robust evidence of a strong interaction between chitosan and the bioactive ingredients, leading to a marked enhancement in both the stability and aqueous solubility of the target compounds. For process optimization, a multi-objective approach was implemented using the Non-dominated Sorting Genetic Algorithm II (NSGA-II) to simultaneously maximize the extraction yields of phillyrin and forsythoside A. The algorithm identified the optimal parameters as a leaf-to-chitosan mass ratio of 10:11.75, a solid-to-liquid ratio of 1:52 g/mL, a temperature of 80 °C, and a duration of 120 min. Under these optimized conditions, the corresponding extraction yields for phillyrin and forsythoside A were 1.68 ± 0.16% and 3.23 ± 0.27%, respectively. These findings collectively indicate that chitosan-assisted extraction represents a highly promising and advanced technology for the sustainable and effective extraction of bioactive ingredients from botanical sources.

08
CLINICAL STUDY Environmental monitoring and assessment (2025) PMID: 40601133 ↗
Identifying the ideal habitats for authentic herbs to cope with climate warming: a case study of Forsythia suspensa.
Clinical Trial Synthesis 2025 Clinical Study published in Environmental monitoring and assessment. Key conclusion: The environmental factors influencing the phillyrin content were significantly negatively correlated with the soil texture classification and precipitation of the driest quarter, whereas the forsythoside A content was significantly negatively correlated with the mean diurnal rang
View Original PubMed Abstract ↓

Forsythia suspensa (Thunb.) Vahl, a widely used medicinal plant, especially its fruits in the green fruit stage, is called "Qingqiao" (QQ). However, the effects of climate change on the quality of QQ have not been reported. Therefore, this study conducts an analysis from the perspective of quality distribution and further proposes future stable distribution areas. In this study, F. suspensa distribution data were collected through field surveys and online sources. Phillyrin and forsythoside A contents from selected QQ production areas were then combined and analyzed via the maximum entropy model alongside stepwise regression equations to assess the potential effects of future climate on QQ quality. The results suggest that under various representative concentration pathway (RCP2.6, RCP4.5, and RCP8.5), the QQ quality areas, which are based on the two key contents, decreased. The environmental factors influencing the phillyrin content were significantly negatively correlated with the soil texture classification and precipitation of the driest quarter, whereas the forsythoside A content was significantly negatively correlated with the mean diurnal range and precipitation of the driest quarter. The stable quality regionalization prediction of F. suspensa is expected to remain mainly in North China, with a northward shift of the centroid suggesting a potential response to global warming. These findings provide a foundation for F. suspensa conservation and sustainable development of these resources. © 2025. The Author(s).

09
CLINICAL STUDY Neuropharmacology (2025) PMID: 40383262 ↗
Forsythoside B suppresses glioblastoma by upregulating the expression of PTPRN.
Clinical Trial Synthesis 2025 Clinical Study published in Neuropharmacology. Key conclusion: Taken together, these results suggest that FB exerts its anticancer effects on GBM via increasing the expression of PTPRN, which may provide a potential new therapeutic strategy for the treatment of GBM.
View Original PubMed Abstract ↓

Glioblastoma (IDH-wildtype) (GBM), the most common high-grade glioma, is a highly invasive and malignant tumor in the brain. Currently, there is no effective treatment for GBM, highlighting the urgent need to find novel therapeutic drugs. Forsythoside B (FB), as a phenylethanoid glycosides compound extracted from Forsythia suspensa, has shown pharmacological functions such as anti-inflammation and anti-bacteria. However, its effects and mechanisms in GBM remain unclear. By performing several in vitro assays, we found that FB suppressed the proliferation of GBM cells in dose- and time-dependent manners. Furthermore, FB arrested the cell cycle at the G0/G1 phase and induced apoptosis in GBM cells. FB also significantly inhibited GBM cells migration. Mechanistically, RNA sequencing results showed that FB treatment remarkably upregulated the expression of PTPRN (a protein-coding gene that plays an important role in the progression of various cancers) in GBM cells. Consistent with this finding, PTPRN expression was downregulated in GBM samples from the Chinese Glioma Genome Atlas (CGGA) and other databases. Knockdown of PTPRN partially restored the inhibitory effects of FB on GBM cells, whereas, overexpression of PTPRN enhanced FB-induced suppression of GBM cell growth and migration. Finally, we found that FB slowed down the growth of tumor in a GBM orthotopic mice model through upregulating PTPRN expression in vivo, with no significant toxicity to other organs. Taken together, these results suggest that FB exerts its anticancer effects on GBM via increasing the expression of PTPRN, which may provide a potential new therapeutic strategy for the treatment of GBM.

10
CLINICAL STUDY Phytotherapy research (2025) PMID: 40342240 ↗
Forsythoside A Alleviates Acute Alcoholic Liver Injury by Binding to TLR4 to Inhibit the Activation of the NF-κB Pathway.
Clinical Trial Synthesis 2025 Clinical Study published in Phytotherapy research. Key conclusion: It binds to TLR4 to inhibit the activation of the NF-κB signaling pathway by alcohol, thereby reducing oxidative stress and inflammation and exerting a protective effect.
View Original PubMed Abstract ↓

Forsythoside A (FTA) is a key component found in the fruit and leaves of Forsythia suspensa, having anti-inflammatory and antioxidant properties. However, it is unclear whether FTA can have a protective effect against acute alcoholic liver injury (ALI) and how it may exert this effect. This research examined the potential protective effects of FTA against acute ALI using cell and animal models. The protective properties of FTA against acute ALI were attributed to its anti-inflammatory and antioxidant actions by detecting the markers of oxidative stress and inflammation. The underlying mechanism was explored through the utilization of Western blotting, Molecular Docking, and Microscale Thermophoresis techniques. The results showed that pretreatment with high doses of FTA had a significant protective effect on acute ALI in both cell and animal models. The pretreatment with high doses of FTA inhibited alcohol-induced oxidative stress and inflammation, raising antioxidative enzyme activity in both models. Furthermore, FTA has been shown to bind to TLR4, thereby inhibiting alcohol-induced activation of the NF-κB signaling pathway, leading to a decrease in cellular oxidative stress and inflammatory reactions. This interaction also facilitates the ubiquitination-mediated degradation of TLR4, ultimately diminishing its regulatory impact on the NF-κB signaling cascade. FTA has a significant protective effect on acute ALI. It binds to TLR4 to inhibit the activation of the NF-κB signaling pathway by alcohol, thereby reducing oxidative stress and inflammation and exerting a protective effect. The results of our study provide a theoretical basis for the development of FTA for the prevention and treatment of acute ALI. © 2025 John Wiley & Sons Ltd.

RELATED MONOGRAPHS

Related Monographs in This Category